PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Chronic obstructive pulmonary disease

Drugs in development · updated 30 October 2026

Chronic obstructive pulmonary disease: drugs in development

As of 30 October 2026 there are 83 active clinical trials (recruiting or ongoing, phases I–III) on 89 drugs for chronic obstructive pulmonary disease. 51 are experimental, that is not yet approved in the United States.

83Active trials
51Experimental drugs
12Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
HSK39004III6NCT07658339
LunsekimigIII3NCT07190222
GSK5784283III2NCT07780656
TilrekimigPF-07275315II–III2NCT07363694
AnoroIII1NCT06474039
AstegolimabIII1NCT05878769
JKN2401III1NCT07330310
REGEND001III1NCT07828353
StapokibartCM310, StapokibatrtII–III1NCT06547333
TrelegyIII1NCT06474039
VaxigripIII1NCT07604103
VerducatibIII1NCT07907991
9MW1911II1NCT07292714
AERO-001II1NCT07896252
AERO-002II1NCT07896252
AERO-007II1NCT07896252
AZD6793II1NCT07082738
BrenipatideII1NCT07759245
CD19I–II1NCT03500731
CM326II1NCT07418736
CM512II1NCT06980142
Dexpramipexole DihydrochlorideII1NCT06533553
EXPD-101II1NCT07684820
FlexlamoseII1NCT06731959
FrespaciguatII1NCT05612035
FXS7553II1NCT07684820
GalvokimigII1NCT07725939
Hemay005II1NCT07314242
HSK31858II1NCT06820749
JKN2403II1NCT07351734
KIT2014I–II1NCT07668518
P63I–II1NCT06946953
PRA-216II1NCT07730281
PsilocybinPsilocybineII1NCT06782724
RademikibartII1NCT07705737
RO7830698I–II1NCT07822334
RSS0343II1NCT07349524
TQC2731II1NCT06707883
TQC2938II1NCT06789289
VerekitugII1NCT06981078

Sorted by most advanced phase and number of active trials. Showing 40 of 51 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DepemokimabExdensur®III3NCT06959095
EnsifentrineOhtuvayre®III2NCT07874815
MetforminRiomet Er®, Glumetza®III2NCT06999343
TadalafilChewtadzy®, Tadliq®III2NCT05844462
TezepelumabTezspireIII2NCT06878261
AspirinVazalore®, Durlaza®III1NCT05265299
AtorvastatinLipitor, Atorvaliq®II–III1NCT04147286
Fluticasone PropionateFluticasone, Xhance®III1NCT06234345
FormoterolPerforomist®, Foradil Certihaler®III1NCT06234345
GlycopyrroniumGlycopyrrolate, Dartisla Odt®III1NCT06234345
LevofloxacinLevaquin®, Iquix®II–III1NCT06859450
NitroglycerinGonitro®, Nitromist®II–III1NCT06785337
UmeclidiniumUMEC, Incruse Ellipta®III1NCT04536675
VilanterolIII1NCT04536675
AlemtuzumabCampath, Lemtrada®I–II1NCT03500731

Sorted by most advanced phase and number of active trials. Showing 15 of 38 drugs.

All 89 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D029424 “Pulmonary Disease, Chronic Obstructive”.

ItalianoFrançaisDeutsch